Investing.com - Financial Markets Worldwide
🎈 Up Big Today: Find today's biggest gainers with our free screenerTry Stock Screener

Ironwood Pharmaceuticals Inc (I76)

Frankfurt
Symbol
Exchange
Currency
IRWDNASDAQUSD
I76FrankfurtEUR
Currency in EUR
3.320
-0.160(-4.60%)
Closed
I76 Scorecard
Full Analysis
High shareholder yield
Fair Value
Unlock Value
Day's Range
3.3203.380
52 wk Range
2.96014.500
Key Statistics
Edit
Bid/Ask
3.34 / 3.38
Prev. Close
3.48
Open
3.38
Day's Range
3.32-3.38
52 wk Range
2.96-14.5
Volume
1
Average Volume (3m)
25
1-Year Change
-65.95%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
I76 Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Technical Analysis
Strong Sell
Analysts Sentiment
Buy
Price Target
12.500
Upside
+254.108%
Members' Sentiments
Bearish
Bullish
ProTips
pro lock
Unlock All 8
Valuation implies a strong free cash flow yield
Unlock InvestingPro

Ironwood Pharmaceuticals Inc News & Analysis

Show more

Ironwood Pharmaceuticals Inc Company Profile

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
219
Market
United States

Compare I76 to Peers and Sector

Metrics to compare
I76
Peers
Sector
Relationship
P/E Ratio
−231.3x−2.6x−0.6x
PEG Ratio
−2.21−0.010.00
Price/Book
−1.8x1.6x2.6x
Price / LTM Sales
1.5x5.6x3.2x
Upside (Analyst Target)
-177.0%49.4%
Fair Value Upside
Unlock25.4%7.8%Unlock

FAQ

What Is the Ironwood (I76) Stock Price Today?

The Ironwood stock price today is 3.32

What Stock Exchange Does Ironwood Trade On?

Ironwood is listed and trades on the Frankfurt stock exchange.

What Is the Stock Symbol for Ironwood?

The stock symbol for Ironwood is "I76."

What Is the Ironwood Market Cap?

As of today, Ironwood market cap is 537.84M.

What is Ironwood Earnings Per Share?

The Ironwood EPS is -0.016.

From a Technical Analysis Perspective, Is I76 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.